Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jacobio Pharmaceuticals
Biotech
Allist pays Jacobio $21M, landing role in Chinese KRAS race
Allist is paying Jacobio Pharma $21 million for rights to a near-approval inhibitor of the KRAS oncogene and a potentially complementary molecule.
Nick Paul Taylor
Aug 30, 2024 9:12am
Jacobio's KRAS data tee up safety-focused lung cancer pitch
May 1, 2024 7:01am
AbbVie sends Chinese biotech's SHP2 pact back to port
Jul 5, 2023 10:50am
HebeCell lands $53M to make a splash in busy CAR-NK space
Sep 1, 2021 8:35am
AbbVie pens cancer pact with U.S.-China biotech Jacobio
Jun 1, 2020 8:30am
